Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

SEC Form 8-K: Press Release dated August 21, 2024

BPTH__20240821_8-K

SEC Form 8-K: Press Release dated August 15, 2024

BPTH_20240815_8-K

SEC Form 10-Q for period ending June 30, 2024

BPTH_2nd_Qtr_20240814_10-Q

SEC Form 8-K: Press Release dated July 8, 2024

BPTH_8-K_07112024

SEC Form 8-K: Press Release dated June 14, 2024

BPTH_Form_8-K_06-14-24_Press_Release

SEC Form 424b3 Prospectus – June 14, 2024

BPTH_Prospectus_Resale_June_2024_PIPEDownload

SEC Form 8-K: re Nasdaq Extension

BPTH_Form_8-K_Nasdaq-Extension

SEC Form S-3

BPTH_Form_S-3_Resale_Registration_Statement_20240611_PIPE

SEC Form 8-K: Press Release dated June 5, 2024

BPTH_8-K_20240605

SEC Form 8-K: Press Release dated June 3, 2024

BPTH_20240602_8-K

Bio-Path Holdings

All Rights Reserved

Office:

625 Stanwix Street
Pittsburgh, PA, 15222

T: (630) 708-0750

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us